Signaling Pathways and Molecular Targets in Cholangiocarcinoma | Chapter 2 | Current Innovations in Disease and Health Research Vol. 5

 Background: The item systematically reviewed existent knowledge on the ancestral basis of CCA, molecular goals/signaling pathways involved in the pathogenesis, ailment progression and forecast, including potential targets for target therapies of CCA. Cholangiocarcinoma (CCA) is the second most frequent hepatobiliary cancer following in position or time hepatocellular carcinoma accompanying a poor prognosis and limited situation options.Methods: The systematic review was acted in compliance accompanying PRISMA guidelines. A systematic search in PubMed and Science Direct databases was acted using the following keywords: “cholangiocarcinoma”, AND “molecular mark” AND/OR “signaling road”, AND/OR “targeted therapy”, AND/OR “tumor chemotherapy.”  The eligibility tests included: i) brimming-text articles written in English, ii) articles accompanying in vitro and/or in vivo and/or clinical studies of microscopic targets/signaling pathways had connection with CCA pathogenesis/disease progress/prognosis and/or targeted medicine. Seventy-three studies that fulfilled the eligibility tests were finally contained in the final data combining.Results: A total of 833 relevant articles written up to April 2022 were labeled and 73 studies that fulfilled the eligibility tests were finally included in the reasoning. The molecular biomarkers and drugs guide signalling pathways were reported. Recent research has directed on targeting the apoptotic and cell increase pathways and the angiogenesis and metastasis pathways. More work focused on testing the efficiency of combination therapies against tumor cells, particularly CCA. The PI3K (Phosphoinositide 3-kinases)/ERK/Akt (AKT serine/threonine kinase 1)/mTOR (mammalian target of rapamycin) indicating pathway and HER2 (Human epidermal growth determinant receptor 2) and EGFR (Epidermal Growth Factor Receptor) pathways are the most potential marks for CCA therapy.Conclusion: The information got could be exploited for further incident of diagnostic forms for early diagnosis of CCA and effective CCA-target therapies.

Author(s) Details:

Kesara Na-Bangchang,
Chulabhorn International College of Medicine, Thammasat University, Rangsit Center, Klong Luang, Pathum Thani-12120, Thailand and Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University, Rangsit Center, Klong Luang, Pathum Thani-12120, Thailand and Drug Discovery and Development Center, Thammasat University, Rangsit Center, Klong Luang, Pathum Thani-12120, Thailand.

Please see the link here: https://stm.bookpi.org/CIDHR-V5/article/view/11583